Filtered By:
Specialty: Hematology
Condition: Hemorrhagic Stroke

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 295 results found since Jan 2013.

Sickle‐cell disease stroke throughout life: A retrospective study in an adult referral center
Abstract Strokes are one of the most severe complications of sickle‐cell disease. Most studies have been restricted to children with sickle‐cell disease. To better understand the characteristics and follow‐up of strokes occurring from childhood to adulthood, we undertook a retrospective cohort study of 69 stroke patients among the 2,875 patients consulting at the French Adult Sickle‐Cell Disease Referral Center. Between 1970 and 2008, they had experienced 104 strokes: 80 ischemic, 22 hemorrhagic and 2 intracranial sinus thromboses. Coma and/or fatal outcomes underscored the severity of strokes in sickle‐cell dise...
Source: American Journal of Hematology - November 8, 2013 Category: Hematology Authors: Antoine Gueguen, Matthieu Mahevas, Ruben Nzouakou, Hassan Hosseini, Anoosha Habibi, Dora Bachir, Pierre Brugière, François Lionnet, Jean‐Antoine Ribeil, Bertrand Godeau, Robert Girot, Vahid Ibrahima, David Calvet, Frédéric Galactéros, Pablo Bartolu Tags: Research Article Source Type: research

Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
Abstract This review article discusses the following, as yet unanswered, questions and research priorities to optimise patient management and stroke prevention in atrial fibrillation with the new direct oral anticoagulants (NOACs): 1. In patients prescribed a NOAC, can the anticoagulant effects or plasma concentrations of the NOACs be measured rapidly and reliably and, if so, can "cut-off points" between which anticoagulation is therapeutic (i.e. the "therapeutic range") be defined? 2. In patients who are taking a NOAC and bleeding (e.g. intracerebral haemorrhage), can the anticoagulant effects of the direct NOACs...
Source: Thrombosis and Haemostasis - November 28, 2013 Category: Hematology Authors: Hankey GJ Tags: Thromb Haemost Source Type: research

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
Abstract The risks of both ischemic and hemorrhagic stroke are particularly high in dialysis patients of any age and outcomes are poor. It is therefore important to identify strategies that safely minimize stroke risk in this population. Observational studies have been unable to clarify the relative importance of traditional stroke risk factors such as blood pressure and cholesterol in those on dialysis, and are affected by biases that usually make them an inappropriate source of data on which to base therapeutic decisions. Well‐conducted randomized trials are not susceptible to such biases and can reliably investigate t...
Source: Seminars In Dialysis - May 1, 2014 Category: Hematology Authors: William Herrington, Richard Haynes, Natalie Staplin, Jonathan Emberson, Colin Baigent, Martin Landray Tags: Review Source Type: research

Acute ischemic stroke patients with diabetes should not be excluded from intravenous thrombolysis
Abstract The benefit of intravenous thrombolysis (IVT) has been questioned for patients with diabetes mellitus (DM) in cases of acute ischemic stroke (IS). Our objective was to analyze the differences in outcome according to prior diagnosis of DM and the use or not of IVT. Observational study with inclusion of consecutive IS patients admitted to an stroke unit. Demographic data, vascular risk factors, comorbidity, stroke severity and 3-month follow-up outcome (modified Rankin Scale) were compared according to prior diagnosis of DM and the use or not of IVT. A total of 1,139 IS patients were admitted; 283 (24.8 %...
Source: Journal of Thrombosis and Thrombolysis - October 2, 2014 Category: Hematology Source Type: research

Effect of anticoagulation on cardioembolic stroke severity, outcomes and response to intravenous thrombolysis
In this study, OAC are not related with response to IVT.
Source: Journal of Thrombosis and Thrombolysis - February 9, 2016 Category: Hematology Source Type: research

α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke
Semin Thromb HemostDOI: 10.1055/s-0036-1585077Thrombotic vascular occlusion is the leading cause of ischemic stroke. High blood levels of α2-antiplasmin (a2AP), an ultrafast, covalent inhibitor of plasmin, have been linked in humans to increased risk of ischemic stroke and failure of tissue plasminogen activator (tPA) therapy. Consistent with these observations, a2AP neutralizes the therapeutic benefit of tPA therapy in experimental stroke. In addition, a2AP has deleterious, dose-related effects on ischemic brain injury in the absence of therapy. Experimental therapeutic inactivation of a2AP markedly reduces microvascular...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2016 Category: Hematology Authors: Reed, Guy L. Houng, Aiilyan K. Singh, Satish Wang, Dong Tags: Review Article Source Type: research

The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis.
Authors: Marszalek J, Mehrsefat S, Chi G Abstract Data from recent randomized controlled trials indicate that the incidence of stroke among acutely ill medical patients is unexpectedly high and approximates 1% at 90 days. Preliminary data suggest that betrixaban may reduce ischemic stroke in patients without atrial fibrillation. There is an unmet demand for stroke risk stratification schemes targeting hospitalized medical patients. The prognostic value of biomarkers such as natriuretic peptides and D-dimer in predicting short-term stroke remains uncertain. Future research should focus on identifying the high-risk s...
Source: Expert Review of Hematology - June 16, 2017 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Incidence, Risk factors, and Biomarkers Predicting Ischemic or Hemorrhagic Stroke Associated Acute Kidney Injury and Outcome: A Retrospective Study in a General Intensive Care Unit
Conclusions: Among stroke patients in ICU, we identified significant risk factors of stroke-associated AKI. Serum CysC level at ICU admission was an important biomarker for predicting AKI and 28-day mortality.Blood Purif
Source: Blood Purification - March 20, 2019 Category: Hematology Source Type: research

Modified diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score including deep white matter lesions predicts symptomatic intracerebral hemorrhage following intravenous thrombolysis
AbstractThe Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is widely used for the assessment of early ischemic changes (EICs) before thrombolysis. However, for symptomatic intracerebral hemorrhage (sICH) following intravenous recombinant tissue plasminogen activator (rt-PA), the prediction abilities of CT-ASPECTS, diffusion-weighted imaging (DWI)-ASPECTS, and DWI-ASPECTS including EICs in deep white matter (DWI-ASPECTS  + W) are unclear. We investigated associations between each score and sICH following intravenous rt-PA. Data from consecutive patients who received intravenous rt-PA for acute ischemic...
Source: Journal of Thrombosis and Thrombolysis - November 18, 2019 Category: Hematology Source Type: research

Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
In conclusion, available evidence from aggregate data supported a modest advantage of ticagrelor-involving regimens for the primary stroke prevention in CAD compared with other antiplatelet regimens after the trade-off between reducing IS and inducing ICH, where more benefits might be expected from long-term and low-dose use of tica grelor among patients with chronic coronary syndrome. Further collaborative meta-analysis of individual participant data from well-designed and statistically-powered trials would be needed to generate high quality evidence on this issue.
Source: Journal of Thrombosis and Thrombolysis - March 26, 2020 Category: Hematology Source Type: research

Thrombolytic strategies for ischemic stroke in the thrombectomy era
J Thromb Haemost. 2021 Apr 9. doi: 10.1111/jth.15336. Online ahead of print.ABSTRACTTwenty-five years ago, intravenous thrombolysis has revolutionized the care of patients with acute ischemic stroke. Since 2015, randomized clinical trials have demonstrated that mechanical thrombectomy improves functional outcome in stroke patients over intravenous thrombolysis alone. More recently, three randomized clinical trials have suggested that mechanical thrombectomy alone is non-inferior to a combined strategy with both intravenous thrombolysis and mechanical thrombectomy. In the present review, we will present the last clinical an...
Source: Thrombosis and Haemostasis - April 9, 2021 Category: Hematology Authors: Maxime Gauberti Sara Martinez de Lizarrondo Denis Vivien Source Type: research

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research